arrow
A

Andrew Calinisan

mirati therapeutics, inc.
H指数:8
被引数:2,687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

SOS1抑制剂MRTX0902阻断KRAS激活并在依赖KRAS核苷酸负载的癌症中显示抗肿瘤活性

2024-04-194
OAAI
Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer
2024-04-050
PRE
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
2024-03-133
OAAI
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

一种有效的选择性非共价KRASG12D抑制剂的抗肿瘤功效

2022-10-10207
OA
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

鉴定非共价,有效和选择性的KRASG12D抑制剂MRTX1133

2021-12-10354
OA
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

KRASG12C抑制剂MRTX849为小鼠模型和患者中KRAS突变癌症的治疗易感性提供了见解

2020-01-09702
OAAI
The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
2019-12-013
PRE